Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
SeaStar Medical Holding Corporation (Nasdaq: ICU) generates news that centers on its development and commercialization of therapies based on its patented Selective Cytopheretic Device (SCD) technology for critically ill patients. Company press releases highlight progress with its first commercial product, QUELIMMUNE (SCD-PED) therapy, which is approved by the U.S. Food and Drug Administration under a Humanitarian Device Exemption for life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients receiving Renal Replacement Therapy.
News updates frequently cover commercial adoption milestones for QUELIMMUNE, including new top-rated children’s hospitals that begin using the therapy and real-world outcomes reported through the SAVE Surveillance Registry. These releases often describe survival data, safety findings such as zero device-related adverse events, and registry enrollment updates that may influence the therapy’s market opportunity.
Investors following ICU news also see regular coverage of clinical development for SCD therapy in adult AKI and cardiovascular indications. This includes announcements related to the NEUTRALIZE-AKI pivotal trial in adults with AKI requiring continuous renal replacement therapy, DSMB recommendations, enrollment progress, and the initiation of studies such as the NEUTRALIZE-CRS trial in patients with acute chronic systolic heart failure and cardiorenal syndrome awaiting LVAD implantation.
Additional SeaStar Medical news items include regulatory and FDA interactions, such as Breakthrough Device Designations for multiple therapeutic indications and adjustments to post-approval surveillance requirements for QUELIMMUNE. Corporate updates, including reverse stock split actions, equity financings, financial results, and executive appointments, are also disclosed through press releases and associated SEC filings. For readers tracking ICU, the news stream provides insight into commercial traction, clinical trial status, regulatory milestones, and key corporate decisions that shape the company’s SCD-based therapy platform.
SeaStar Medical Holding Corporation (Nasdaq: ICU) appointed Rick Barnett as Chairman of its Board of Directors. Barnett, a board member since January 2021, brings extensive experience in healthcare and medical device industries. He previously led Satellite Healthcare and currently serves on other boards. CEO Eric Schlorff highlighted that Barnett's commercial expertise will enhance the company's growth strategy as they approach a potential commercial launch of their SCD product candidate in Q2 2023. SeaStar Medical focuses on therapies to mitigate hyperinflammation risks in critical patients.
SeaStar Medical (Nasdaq: ICU) announced its Selective Cytopheretic Device (SCD) is included in the Consensus Statement for pediatric acute kidney injury (AKI) by the Pediatric Acute Disease Quality Initiative. The FDA is currently reviewing the HDE application for SCD, which expects completion by Q1 2023, with potential commercial launch in Q2 2023. This therapy aims to reduce inflammation and improve outcomes for critically ill children with AKI, a condition affecting approximately 4,000 pediatric patients annually in the U.S.
SeaStar Medical announced positive interim data for its Selective Cytopheretic Device (SCD) at the American Society of Nephrology Kidney Week 2022. The device is being tested in pediatric patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy. Interim findings indicate safety and an 83% survival rate, outperforming a historical 50% benchmark. The FDA is reviewing the SCD for a Humanitarian Device Exemption, with possible approval by Q1 2023 and a commercial launch anticipated in Q2 2023.
SeaStar Medical, trading under the ticker ICU, has begun its journey on the Nasdaq following a successful business combination with LMF Acquisition Opportunities. The company aims to advance its Selective Cytopheretic Device (SCD) to treat hyperinflammation, focusing on pediatric and adult Acute Kidney Injury (AKI). Regulatory milestones include potential FDA approval for pediatric AKI in Q1 2023 and a pivotal trial in adult AKI also commencing in Q1 2023. The company's innovative therapy is designed to neutralize pro-inflammatory cells, aiming to significantly improve patient outcomes.